Nanomedicines in the future of pediatric therapy

Advanced Drug Delivery Reviews

Volumn 73, Issue , 2014, Pages 140-161

  Sosnik, Alejandro ^a   Carcaboso, Angel M ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Cancer; HIV AIDS; Malaria; Pediatric nanomedicine; Tuberculosis

Indexed keywords

DISEASES; MEDICAL NANOTECHNOLOGY; NANOTECHNOLOGY; PEDIATRICS;

CANCER; CLINICAL EXPERIENCE; HIV/AIDS; INNOVATIVE TECHNOLOGY; MALARIA; PEDIATRIC POPULATION; PHARMACOKINETICS AND PHARMACODYNAMICS; TUBERCULOSIS; SCIENTIFIC EVIDENCE;

PEDIATRICS; DISEASES;

AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; ARTEMETHER; BENFLUMETOL; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CPX 351; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LOMUSTINE; MEFLOQUINE; MIFAMURTIDE; NANOPARTICLE; PACLITAXEL; PYRAZINAMIDE; PYRONARIDINE; RIFAMPICIN; THERMODOX; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; VINCRISTINE SULFATE; ANNAMYCIN; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE PLUS MEFLOQUINE; ARTESUNATE PLUS PYRONARIDINE; CURCUMIN; CYCLODEXTRIN; CYTARABINE PLUS DAUNORUBICIN; FIRTECAN; GOLD PORPHYRIN; MIGLYOL; POLOXAMER; POLYMER; PORPHYRIN DERIVATIVE; PRIMAQUINE; SMALL INTERFERING RNA; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AREA UNDER THE CURVE; ASTROCYTOMA; BODY SURFACE; BODY WEIGHT; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CHILD; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RECEPTOR BINDING; EWING SARCOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INFECTION; MALARIA; MAXIMUM PLASMA CONCENTRATION; MEDULLOBLASTOMA; NANOMEDICINE; NANOTECHNOLOGY; NEOPLASM; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PEDIATRICS; PHARMACODYNAMICS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RAT; RETINOBLASTOMA; REVIEW; RHABDOMYOSARCOMA; SOLID TUMOR; TUBERCULOSIS; ANIMAL; COMMUNICABLE DISEASES; NEOPLASMS; BREAST CANCER; BURNING MOUTH SYNDROME; CENTRAL NERVOUS SYSTEM LEUKEMIA; CHILD HEALTH CARE; CHILDHOOD CANCER; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SOLUBILITY; GLIOMA; MUCOSA INFLAMMATION; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SINGLE DRUG DOSE;

ANIMALS; CHILD; COMMUNICABLE DISEASES; HUMANS; NANOMEDICINE; NEOPLASMS; PEDIATRICS;

EID: 84902345856     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.05.004     Document Type: Review

References (288)

1. Kim B.Y., Rutka J.T., Chan W.C. Nanomedicine. N. Engl. J. Med. 2010, 363:2434-2443.
2. Wagner V., Dullaart A., Bock A.K., Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol. 2006, 24:1211-1217.
3. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6:688-701.
4. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63:136-151.
5. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 2010, 188:759-768.
6. Chowdhury N. Regulation of nanomedicines in the EU: distilling lessons from the pediatric and the advanced therapy medicinal products approaches. Nanomedicine (Lond.) 2010, 5:135-142.
7. Etheridge M.L., Campbell S.A., Erdman A.G., Haynes C.L., Wolf S.M., McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 2013, 9:1-14.
8. Kearns G.L., Abdel-Rahman S.M., Alander S.W., Blowey D.L., Leeder J.S., Kauffman R.E. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 2003, 349:1157-1167.
9. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH E 11 Clinical Investigation of Medicinal Products in the Paediatric Population (CPMP/ICH/2711/99). London, 2000. Guidance on E 11 Clinical Investigation of Medicinal Products in Pediatric Population; Notice. Federal Register, 2000 2003, 65:78493-78494. Cambridge University Press.
10. Pui C.H., Gajjar A.J., Kane J.R., Qaddoumi I.A., Pappo A.S. Challenging issues in pediatric oncology. Nat. Rev. Clin. Oncol. 2011, 8:540-549.
11. Klassen T.P., Hartling L., Craig J.C., Offringa M. Children are not just small adults: the urgent need for high-quality trial evidence in children. PLoS Med. 2008, 5:e172.
12. Moore P. Children are not small adults. Lancet 1998, 352:630.
13. Strolin Benedetti M., Whomsley R., Baltes E.L. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin. Drug Metab. Toxicol. 2005, 1:447-471.
14. James L.P., Marotti T., Stowe C.D., Farrar H.C., Taylor B.J., Kearns G.L. Pharmacokinetics and pharmacodynamics of famotidine in infants. J. Clin. Pharmacol. 1998, 38:1089-1095.
15. Marshall J.D., Kearns G.L. Developmental pharmacodynamics of cyclosporine. Clin. Pharmacol. Ther. 1999, 66:66-75.
16. Takahashi H., Ishikawa S., Nomoto S., Nishigaki Y., Ando F., Kashima T., Kimura S., Kanamori M., Echizen H. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin. Pharmacol. Ther. 2000, 68:541-555.
17. Bridge J.A., Iyengar S., Salary C.B., Barbe R.P., Birmaher B., Pincus H.A., Ren L., Brent D.A. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007, 297:1683-1696.
18. Sosnik A., Seremeta K.P., Imperiale J.C., Chiappetta D.A. Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases. Expert Opin. Drug Deliv. 2012, 9:303-323.
19. Bowles A., Keane J., Ernest T., Clapham D., Tuleu C. Specific aspects of gastro-intestinal transit in children for drug delivery design. Int. J. Pharm. 2010, 395:37-43.
20. Semmler-Behnke M., Kreyling W.G., Schulz H., Takenaka S., Butler J.P., Henry F.S., Tsuda A. Nanoparticle delivery in infant lungs. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:5092-5097.
21. Standing J.F., Tuleu C. Paediatric formulations-getting to the heart of the problem. Int. J. Pharm. 2005, 300:56-66.
22. Formulations of choice for the paediatric population, committee for medicinal products for human use, EMA (London 23 June 2005 EMEA/CHMP/PEG/194810/2005), in (last accessed November 2011). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003782.pdf.
23. Guideline on pharmaceutical development of medicines for paediatric use, EMA (London 19 May 2011 EMA/CHMP/QWP/180157/2011), in (last accessed 23 June 2013). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/06/WC500107908.pdf.
24. Nahata M.C., Allen L.V. Extemporaneous drug formulations. Clin. Ther. 2008, 30:2112-2119.
25. Osuntokun B. Clinical trials in pediatrics: the drug delivery dimension. Adv. Drug Deliv. Rev. 2006, 58:90-105.
26. Chappuy H., Doz F., Blanche S., Gentet J.C., Pons G., Treluyer J.M. Parental consent in paediatric clinical research. Arch. Dis. Child. 2006, 91:112-116.
27. Gans-Brangs K.R., Plourde P.V. The evolution of legislation to regulate pediatric clinical trials: present and continuing challenges. Adv. Drug Deliv. Rev. 2006, 58:106-115.
28. Sly P.D., Schuepp K. Nanoparticles and children's lungs: is there a need for caution?. Paediatr. Respir. Rev. 2012, 13:71-72.
29. Verschraegen C.F., Gilbert B.E., Loyer E., Huaringa A., Walsh G., Newman R.A., Knight V. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin. Cancer Res. 2004, 10:2319-2326.
30. Okusanya O.O., Bhavnani S.M., Hammel J., Minic P., Dupont L.J., Forrest A., Mulder G.J., Mackinson C., Ambrose P.G., Gupta R. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob. Agents Chemother. 2009, 53:3847-3854.
31. Ryman-Rasmussen J.P., Cesta M.F., Brody A.R., Shipley-Phillips J.K., Everitt J.I., Tewksbury E.W., Moss O.R., Wong B.A., Dodd D.E., Andersen M.E., Bonner J.C. Inhaled carbon nanotubes reach the subpleural tissue in mice. Nat. Nanotechnol. 2009, 4:747-751.
32. Milne C.P., Bruss J.B. The economics of pediatric formulation development for off-patent drugs. Clin. Ther. 2008, 30:2133-2145.
33. Zisowsky J., Krause A., Dingemanse J. Drug development for pediatric populations: regulatory aspects. Pharmaceutics 2010, 2:364-388.
34. The Top Ten Causes of Death 2011, World Health Organization, Geneva, Switzerland, (http://www.who.int/mediacentre/factsheets/fs310/en/index.html, (last accessed in April 2014)).
35. Global report: UNAIDS report on the global AIDS epidemic 2012, in, http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf, (last accessed June 2013).
36. Giaquinto C., Morelli E., Fregonese F., Rampon O., Penazzato M., de Rossi A., D'Elia R. Current and future antiretroviral treatment options in paediatric HIV infection. Clin. Drug Investig. 2008, 28:375-397.
37. Hazra R., Siberry G.K., Mofenson L.M. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu. Rev. Med. 2010, 61:169-185.
38. Stoltenberg I., Winzenburg G., Breitkreutz J. Solid oral dosage forms for children - formulations, excipients and acceptance issues. Eur. Ind. Pharm. 2011, 8:4-7.
39. Kayitare E., Vervaet C., Ntawukulilyayo J.D., Seminega B., Bortel V., Remon J.P. Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications. Int. J. Pharm. 2009, 370:41-46.
40. Padmavathi Y., Madhava Reddy B., Amareswar P. Development of fixed dose combination dispersible tablets containing stavudine, lamivudine and nevirapine for paediatric applications. Int. J. Pharm. Technol. 2011, 3:2343-2352.
41. Pensi T. Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report. Indian Pediatr. 2007, 44:519-521.
42. Chang R., Guo X., Burnside B., Couch R. A review of fast dissolving tablets. Pharm Tech. (North. America). June, 2000:52-58. Pharm. Technol. 2000, 12:52-58.
43. Siddiqui N., Garg G., Sharma P.K. Fast dissolving tablets: preparation, characterization and evaluation: an overview. Int. J. Pharm. Sci. Rev. Res. 2010, 4:87-96.
44. Hirani J.J., Rathod D.A., Vadalia K.R. Orally disintegrating tablets: a review. Trop. J. Pharm. Res. 2009, 8:161-172.
45. Waning B., Diedrichsen E., Jambert E., Barnighausen T., Li Y., Pouw M., Moon S. The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children. BMC Pediatr. 2010, 10:74.
46. Chokephaibulkit K., Cressey T.R., Capparelli E., Sirisanthana V., Muresan P., Hongsiriwon S., Ngampiyaskul C., Limwongse C., Wittawatmongkol O., Aurpibul L., Kabat B., Toye M., Smith M.E., Eksaengsri A., McIntosh K., Yogev R. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. Antivir. Ther. 2011, 16:1287-1295.
47. Sosnik A., Amiji M. Nanotechnology solutions for infectious diseases in developing nations. Preface. Adv. Drug Deliv. Rev. 2010, 62:375-377.
48. Sosnik A. Nanotechnology contributions to the pharmacotherapy of pediatric HIV: a dual scientific and ethical challenge and a still pending agenda. Nanomedicine (Lond.) 2010, 5:833-837.
49. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 2004, 3:785-796.
50. Chan H.K., Kwok P.C. Production methods for nanodrug particles using the bottom-up approach. Adv. Drug Deliv. Rev. 2011, 63:406-416.
51. Muller R.H., Gohla S., Keck C.M. State of the art of nanocrystals-special features, production, nanotoxicology aspects and intracellular delivery. Eur. J. Pharm. Biopharm. 2011, 78:1-9.
52. Gupta U., Jain N.K. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv. Drug Deliv. Rev. 2010, 62:478-490.
53. Van Gyseghem E., Pendela M., Baert L., Rosier J., Van 't Klooster G., De Man H., Bouche M.P., Schueller L., Van Remoortere P., Wigerinck P., Adams E., Hoogmartens J., Van den Mooter G. Powder for reconstitution of the anti-HIV-1 drug TMC278 - formulation development, stability and animal studies. Eur. J. Pharm. Biopharm. 2008, 70:853-860.
54. Jain S., Sharma J.M., Agrawal A.K., Mahajan R.R. Surface stabilized efavirenz nanoparticles for oral bioavailability enhancement. J. Biomed. Nanotechnol. 2013, 9:1862-1874.
55. Sosnik A., Carcaboso A.M., Chiappetta D.A. Polymeric nanocarriers: new endeavors for the optimization of the technological aspects of drugs. Recent Pat. Biomed. Eng. 2010, 1:43-59.
56. Chiappetta D.A., Sosnik A. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. Eur. J. Pharm. Biopharm. 2007, 66:303-317.
57. Sosnik A. Temperature- and pH-sensitive polymeric micelles for drug encapsulation, release and targeting. Smart Materials for Drug Delivery 2013, 115-147. London, Royal Society of Chemistry, [Chapter 5]. C. Alvarez-Lorenzo, A. Concheiro (Eds.).
58. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003, 2:347-360.
59. Kwon G.S. Polymeric micelles for delivery of poorly water-soluble compounds. Crit. Rev. Ther. Drug Carrier Syst. 2003, 20:357-403.
60. Batrakova E.V., Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control. Release 2008, 130:98-106.
61. Bromberg L. Polymeric micelles in oral chemotherapy. J. Control. Release 2008, 128:99-112.
62. Gaucher G., Satturwar P., Jones M.C., Furtos A., Leroux J.C. Polymeric micelles for oral drug delivery. Eur. J. Pharm. Biopharm. 2010, 76:147-158.
63. Jain R., Nabar S., Dandekar P., Hassan P., Aswal V., Talmon Y., Shet T., Borde L., Ray K., Patravale V. Formulation and evaluation of novel micellar nanocarrier for nasal delivery of sumatriptan. Nanomedicine (Lond.) 2010, 5:575-587.
64. Chiappetta D.A., Hocht C., Opezzo J.A., Sosnik A. Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. Nanomedicine (Lond.) 2013, 8:223-237.
65. Pepic I., Lovric J., Filipovic-Grcic J. Polymeric micelles in ocular drug delivery: rationale, strategies and challenges. Chem. Biochem. Eng. Q. 2012, 26:365-377.
66. Ribeiro A., Sosnik A., Chiappetta D.A., Veiga F., Concheiro A., Alvarez-Lorenzo C. Single and mixed poloxamine micelles as nanocarriers for solubilization and sustained release of ethoxzolamide for topical glaucoma therapy. J. R. Soc. Interface 2012, 9:2059-2069.
67. Alvarez-Lorenzo C., Sosnik A., Concheiro A. PEO-PPO block copolymers for passive micellar targeting and overcoming multidrug resistance in cancer therapy. Curr. Drug Targets 2011, 12:1112-1130.
68. A. Sosnik, D.A. Chiappetta, C. Hocht, Composiciones farmacéuticas en forma de soluciones acuosas destinadas a la administración oral de agentes antirretrovirales, Patent Application, AR 072715, in, Argentina, 2009.
69. Chiappetta D.A., Hocht C., Taira C., Sosnik A. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. Nanomedicine (Lond.) 2010, 5:11-23.
70. Chiappetta D.A., Hocht C., Taira C., Sosnik A. Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles. Biomaterials 2011, 32:2379-2387.
71. Chiappetta D.A., Hocht C., Sosnik A. A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate pediatric management of the anti-HIV therapy. Curr. HIV Res. 2010, 8:223-231.
72. Chiappetta D.A., Alvarez-Lorenzo C., Rey-Rico A., Taboada P., Concheiro A., Sosnik A. N-alkylation of poloxamines modulates micellar assembly and encapsulation and release of the antiretroviral efavirenz. Eur. J. Pharm. Biopharm. 2010, 76:24-37.
73. Chiappetta D.A., Facorro G., de Celis E.R., Sosnik A. Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles. Nanomedicine 2011, 7:624-637.
74. Sellers R.S., Antman M., Phillips J., Khan K.N., Furst S.M. Effects of miglyol 812 on rats after 4weeks of gavage as compared with methylcellulose/tween 80. Drug Chem. Toxicol. 2005, 28:423-432.
75. Breitkreutz J., Boos J. Paediatric and geriatric drug delivery. Expert Opin. Drug Deliv. 2007, 4:37-45.
76. Fabiano V., Mameli C., Zuccotti G.V. Paediatric pharmacology: remember the excipients. Pharmacol. Res. 2011, 63:362-365.
77. Nueva formulación pediátrica de efavirenz. Administración Nacional de Medicamentos, Alimentos y Tecnología Médica in, (asp, (last accessed June 2013)). http://www.anmat.gov.ar/apoyo_innovacion/aprobados/NUEVA%20FORMULACION%20PEDIATRICA%20DE%20EFAVIRENZ%20Se%20plantea%20el%20estudio%20en%20un%20voluntario%20en%20Julio%20de%202011.
78. Vivithanaporn P., Gill M.J., Power C. Impact of current antiretroviral therapies on neuroAIDS. Expert Rev. Anti-Infect. Ther. 2011, 9:371-374.
79. Grovit-Ferbas K., Harris-White M.E. Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction. Immunol. Res. 2010, 48:40-58.
80. Van Rie A., Mupuala A., Dow A. Impact of the HIV/AIDS epidemic on the neurodevelopment of preschool-aged children in Kinshasa, Democratic Republic of the Congo. Pediatrics 2008, 122:e123-e128.
81. Brewster M.E., Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 2007, 59:645-666.
82. Glisoni R.J., Chiappetta D.A., Moglioni A.G., Sosnik A. Novel 1-indanone thiosemicarbazone antiviral candidates: aqueous solubilization and physical stabilization by means of cyclodextrins. Pharm. Res. 2012, 9:739-755.
83. Glisoni R.J., Cuestas M.L., Mathet V.L., Oubina J.R., Moglioni A.G., Sosnik A. Antiviral activity against the hepatitis C virus (HCV) of 1-indanone thiosemicarbazones and their inclusion complexes with hydroxypropyl-beta-cyclodextrin. Eur. J. Pharm. Sci. 2012, 47:596-603.
84. Stella V.J., He Q. Cyclodextrins. Toxicol. Pathol. 2008, 36:30-42.
85. Buchanan C.M., Buchanan N.L., Edgar K.J., Little J.L., Ramsey M.G., Ruble K.M., Wacher V.J., Wempe M.F. Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-beta-cyclodextrin formulations. Biomacromolecules 2008, 9:305-313.
86. Sathigari S., Chadha G., Lee Y.H., Wright N., Parsons D.L., Rangari V.K., Fasina O., Babu R.J. Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes. AAPS PharmSciTech 2009, 10:81-87.
87. Shabir A., Mohammed A. Exploring the use of cyclodextrins as carriers in paediatric formulations. Br. J. Clin. Pharm. 2010, 2:275-278.
88. Global Tuberculosis Report 2011, World Health Organization, Geneva, Switzerland, http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf, (last accessed June 2013).
89. Kaufmann S.H., McMichael A.J. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat. Med. 2005, 11:S33-S44.
90. Frieden T.R., Sterling T.R., Munsiff S.S., Watt C.J., Dye C. Tuberculosis. Lancet 2003, 362:887-899.
91. Elder N.C. Extrapulmonary tuberculosis. A review. Arch. Fam. Med. 1992, 1:91-98.
92. Onyebujoh P., Zumla A., Ribeiro I., Rustomjee R., Mwaba P., Gomes M., Grange J.M. Treatment of tuberculosis: present status and future prospects. Bull. World Health Organ. 2005, 83:857-865.
93. Treatment of Tuberculosis: Guidelines 2010, World Health Organization, Geneva, Switzerland, (http://whqlibdoc.who.int/publications/2010/9789241547 833_eng.pdf, (last accessed June 2013)). 4th ed.
94. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., Gordon S.V., Eiglmeier K., Gas S., Barry C.E., Tekaia F., Badcock K., Basham D., Brown D., Chillingworth T., Connor R., Davies R., Devlin K., Feltwell T., Gentles S., Hamlin N., Holroyd S., Hornsby T., Jagels K., Krogh A., McLean J., Moule S., Murphy L., Oliver K., Osborne J., Quail M.A., Rajandream M.A., Rogers J., Rutter S., Seeger K., Skelton J., Squares R., Squares S., Sulston J.E., Taylor K., Whitehead S., Barrell B.G. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393:537-544.
95. WHO The Top Ten Causes of Death 2011, World Health Organization, Geneva, Switzerland, (http://www.who.int/mediacentre/factsheets/fs310/en/index.html, (last accessed June 2013)).
96. Swaminathan S., Rekha B. Pediatric tuberculosis: global overview and challenges. Clin. Infect. Dis. 2010, 50(Suppl. 3):S184-S194.
97. Sosnik A., Carcaboso A.M., Glisoni R.J., Moretton M.A., Chiappetta D.A. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv. Drug Deliv. Rev. 2010, 62:547-559.
98. WHO List of prequalified medicinal products in, (last accessed June 2013). http://apps.who.int/prequal/query/productregistry.aspx.
99. Singh S., Mariappan T.T., Sharda N., Kumar S., Chakraborti A.K. The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions. Pharm. Pharmacol. Commun. 2000, 6:405-410.
100. Shishoo C.J., Shah S.A., Rathod I.S., Savale S.S., Kotecha J.S., Shah P.B. Stability of rifampicin in dissolution medium in presence of isoniazid. Int. J. Pharm. 1999, 190:109-123.
101. Sankar R., Sharda N., Singh S. Behavior of decomposition of rifampicin in the presence of isoniazid in the pH range 1-3. Drug Dev. Ind. Pharm. 2003, 29:733-738.
102. Shishoo C.J., Shah S.A., Rathod I.S., Savale S.S., Vora M.J. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int. J. Pharm. 2001, 228:53-67.
103. Singh S., Mariappan T.T., Shankar R., Sarda N., Singh B. A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int. J. Pharm. 2001, 228:5-17.
104. Pandey R., Zahoor A., Sharma S., Khuller G.K. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb) 2003, 83:373-378.
105. Sharma A., Sharma S., Khuller G.K. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother. 2004, 54:761-766.
106. Pandey R., Sharma S., Khuller G.K. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb) 2005, 85:415-420.
107. Swai H., Semete B., Kalombo L., Chelule P. Potential of treating tuberculosis with a polymeric nano-drug delivery system. J. Control. Release 2008, 132:e48.
108. Booysen L.L., Kalombo L., Brooks E., Hansen R., Gilliland J., Gruppo V., Lungenhofer P., Semete-Makokotlela B., Swai H.S., Kotze A.F., Lenaerts A., du Plessis L.H. In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid. Int. J. Pharm. 2013, 444:10-17.
109. Moretton M.A., Glisoni R., Chiappetta D.A., Sosnik A. Synthesis and characterization of amphiphilic poly(épsilon-caprolactone)-poly(ethyleneglycol) block copolymers. Optimization of the solubility and stability of rifampicin by means of encapsulation into polymeric micelles. I Workshop on Artificial Organs, Biomaterials and Tissue Engineering, Latin American Society of Biomaterials, Tissue Engineering and Artificial Organs (SLABO), Rosario, Argentina 2009.
110. Moretton M.A., Glisoni R.J., Chiappetta D.A., Sosnik A. Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles. Colloids Surf. B: Biointerfaces 2010, 79:467-479.
111. Moretton M.A., Chiappetta D.A., Sosnik A. Cryoprotection-lyophilization and physical stabilization of rifampicin-loaded flower-like polymeric micelles. J. R. Soc. Interface 2012, 9:487-502.
112. Moretton M.A. Estudios de nano-encapsulación de rifampicina en micelas poliméricas para su potencial aplicación en el tratamiento de la tuberculosis 2013, (PhD Thesis), Universidad de Buenos Aires.
113. Moretton M.A., Hocht C., Taira C., Sosnik A. Rifampicin-loaded 'flower-like' polymeric micelles for enhanced oral bioavailability in an extemporaneous liquid fixed-dose combination with isoniazid. Nanomedicine 2014, 1-16.
114. Andrade F., Rafael D., Videira M., Ferreira D., Sosnik A., Sarmento B. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv. Drug Deliv. Rev. 2013, 65:1816-1827.
115. Guideline in the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary diseases (COPD) in, (last accessed June 2013). http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003551.pdf.
116. Deol P., Khuller G.K. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim. Biophys. Acta 1997, 1334:161-172.
117. Pandey R., Khuller G.K. Antitubercular inhaled therapy: opportunities, progress and challenges. J. Antimicrob. Chemother. 2005, 55:430-435.
118. Sharma R., Saxena D., Dwivedi A.K., Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 2001, 18:1405-1410.
119. Mizoe T., Ozeki T., Okada H. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles. AAPS PharmSciTech 2008, 9:755-761.
120. Emami J., Hamishehkar H., Najafabadi A.R., Gilani K., Minaiyan M., Mahdavi H., Mirzadeh H., Fakhari A., Nokhodchi A. Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology. J. Microencapsul. 2009, 26:1-8.
121. Tsifansky M.D., Yeo Y., Evgenov O.V., Bellas E., Benjamin J., Kohane D.S. Microparticles for inhalational delivery of antipseudomonal antibiotics. AAPS J. 2008, 10:254-260.
122. Muttil P., Kaur J., Kumar K., Yadav A.B., Sharma R., Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 2007, 32:140-150.
123. Ohashi K., Kabasawa T., Ozeki T., Okada H. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Control. Release 2009, 135:19-24.
124. Moretton M.A., Chiappetta D.A., Andrade F., das Neves J., Ferreira D., Sarmento B., Sosnik A. Hydrolyzed galactomannan-modified nanoparticles and flower-like polymeric micelles for the active targeting of rifampicin to macrophages. J. Biomed. Nanotechnol. 2013, 9:1076-1087.
125. World Health Organization World Malaria Report in, (last accessed June 2013). http://www.who.int/malaria/publications/world_malaria_report_2012/wmr2012_no_profiles.pdf.
126. World Health Organization Malaria fact sheet in, (last accessed June 2013). http://www.who.int/mediacentre/factsheets/fs094/en/.
127. Kurth F., Belard S., Adegnika A.A., Gaye O., Kremsner P.G., Ramharter M. Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. Lancet Infect. Dis. 2010, 10:125-132.
128. Salah M.T., Faroug M., Magzoub M.M., Adam I. Efficacy of artemether-lumfantrine (Co-Artesiane(r)) suspension in the treatment of uncomplicated Plasmodium falciparum malaria among children under 5years in eastern Sudan. Trop. J. Pharm. Res. 2006, 5:551-555.
129. Abdulla S., Sagara I., Borrmann S., D'Alessandro U., Gonzalez R., Hamel M., Ogutu B., Martensson A., Lyimo J., Maiga H., Sasi P., Nahum A., Bassat Q., Juma E., Otieno L., Bjorkman A., Beck H.P., Andriano K., Cousin M., Lefevre G., Ubben D., Premji Z. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 2008, 372:1819-1827.
130. Juma E.A., Obonyo C.O., Akhwale W.S., Ogutu B.R. A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya. Malar. J. 2008, 7:262.
131. Ramharter M., Kurth F., Schreier A.C., Nemeth J., Glasenapp I., Belard S., Schlie M., Kammer J., Koumba P.K., Cisse B., Mordmuller B., Lell B., Issifou S., Oeuvray C., Fleckenstein L., Kremsner P.G. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J. Infect. Dis. 2008, 198:911-919.
132. Bouyou-Akotet M.K., Ramharter M., Ngoungou E.B., Mamfoumbi M.M., Mihindou M.P., Missinou M.A., Kurth F., Belard S., Agnandji S.T., Issifou S., Heidecker J.L., Trapp S., Kremsner P.G., Kombila M. Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon. Wien. Klin. Wochenschr. 2010, 122:173-178.
133. Santos-Magalhaes N.S., Mosqueira V.C. Nanotechnology applied to the treatment of malaria. Adv. Drug Deliv. Rev. 2010, 62:560-575.
134. Shah P.P., Mashru R.C. Palatable reconstitutable dry suspension of artemether for flexible pediatric dosing using cyclodextrin inclusion complexation. Pharm. Dev. Technol. 2010, 15:276-285.
135. Shah P.P., Mashru R.C. Formulation and evaluation of taste masked oral reconstitutable suspension of primaquine phosphate. AAPS PharmSciTech 2008, 9:1025-1030.
136. Vassal G., Zwaan C.M., Ashley D., Le Deley M.C., Hargrave D., Blanc P., Adamson P.C. New drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncol. 2013, 14:e117-e124.
137. Mora J. What is a pediatric tumor?. Clin. Oncol. Adolesc. Young Adults 2012, 2:7-15.
138. Orentas R.J., Lee D.W., Mackall C. Immunotherapy targets in pediatric cancer. Front. Oncol. 2012, 2:3.
139. Zhang L., Marrano P., Kumar S., Leadley M., Elias E., Thorner P., Baruchel S. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors. Clin. Cancer Res. 2013, 19:5972-5983.
140. Steichen S.D., Caldorera-Moore M., Peppas N.A. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur. J. Pharm. Sci. 2012, 48:416-427.
141. Federman N., Denny C.T. Targeting liposomes toward novel pediatric anticancer therapeutics. Pediatr. Res. 2010, 67:514-519.
142. Marina N.M., Cochrane D., Harney E., Zomorodi K., Blaney S., Winick N., Bernstein M., Link M.P. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin. Cancer Res. 2002, 8:413-418.
143. van Dalen E.C., Michiels E.M., Caron H.N., Kremer L.C. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst. Rev. 2006, CD005006.
144. Seif A.E., Reilly A.F., Rheingold S.R. Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature. J. Pediatr. Hematol. Oncol. 2010, 32:e349-e352.
145. Hong Y., Shaw P.J., Nath C.E., Yadav S.P., Stephen K.R., Earl J.W., McLachlan A.J. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob. Agents Chemother. 2006, 50:935-942.
146. Devi G.R. siRNA-based approaches in cancer therapy. Cancer Gene Ther. 2006, 13:819-829.
147. Miele E., Spinelli G.P., Di Fabrizio E., Ferretti E., Tomao S., Gulino A. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int. J. Nanomedicine 2012, 7:3637-3657.
148. Zhou Q., Guo X., Chen T., Zhang Z., Shao S., Luo C., Li J., Zhou S. Target-specific cellular uptake of folate-decorated biodegradable polymer micelles. J. Phys. Chem. B 2011, 115:12662-12670.
149. Marotta D.E., Cao W., Wileyto E.P., Li H., Corbin I., Rickter E., Glickson J.D., Chance B., Zheng G., Busch T.M. Evaluation of bacteriochlorophyll-reconstituted low-density lipoprotein nanoparticles for photodynamic therapy efficacy in vivo. Nanomedicine (Lond.) 2011, 6:475-487.
150. Baker D.L., Schmidt M.L., Cohn S.L., Maris J.M., London W.B., Buxton A., Stram D., Castleberry R.P., Shimada H., Sandler A., Shamberger R.C., Look A.T., Reynolds C.P., Seeger R.C., Matthay K.K. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N. Engl. J. Med. 2010, 363:1313-1323.
151. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
152. Zage P.E., Louis C.U., Cohn S.L. New aspects of neuroblastoma treatment: ASPHO 2011 symposium review. Pediatr. Blood Cancer 2012, 58:1099-1105.
153. Modak S., Cheung N.K. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Investig. 2007, 25:67-77.
154. Pagnan G., Stuart D.D., Pastorino F., Raffaghello L., Montaldo P.G., Allen T.M., Calabretta B., Ponzoni M. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects. J. Natl. Cancer Inst. 2000, 92:253-261.
155. Brignole C., Pastorino F., Marimpietri D., Pagnan G., Pistorio A., Allen T.M., Pistoia V., Ponzoni M. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J. Natl. Cancer Inst. 2004, 96:1171-1180.
156. Pastorino F., Brignole C., Di Paolo D., Nico B., Pezzolo A., Marimpietri D., Pagnan G., Piccardi F., Cilli M., Longhi R., Ribatti D., Corti A., Allen T.M., Ponzoni M. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res. 2006, 66:10073-10082.
157. Di Paolo D., Brignole C., Pastorino F., Carosio R., Zorzoli A., Rossi M., Loi M., Pagnan G., Emionite L., Cilli M., Bruno S., Chiarle R., Allen T.M., Ponzoni M., Perri P. Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. Mol. Ther. 2011, 19:1131-1140.
158. Tivnan A., Orr W.S., Gubala V., Nooney R., Williams D.E., McDonagh C., Prenter S., Harvey H., Domingo-Fernandez R., Bray I.M., Piskareva O., Ng C.Y., Lode H.N., Davidoff A.M., Stallings R.L. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One 2012, 7:e38129.
159. Jiao P., Zhou H., Otto M., Mu Q., Li L., Su G., Zhang Y., Butch E.R., Snyder S.E., Jiang G., Yan B. Leading neuroblastoma cells to die by multiple premeditated attacks from a multifunctionalized nanoconstruct. J. Am. Chem. Soc. 2011, 133:13918-13921.
160. Wang C.H., Huang Y.J., Chang C.W., Hsu W.M., Peng C.A. In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody. Nanotechnology 2009, 20:315101.
161. Lam C.W., James J.T., McCluskey R., Arepalli S., Hunter R.L. A review of carbon nanotube toxicity and assessment of potential occupational and environmental health risks. Crit. Rev. Toxicol. 2006, 36:189-217.
162. Pastorino F., Loi M., Sapra P., Becherini P., Cilli M., Emionite L., Ribatti D., Greenberger L.M., Horak I.D., Ponzoni M. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Clin. Cancer Res. 2010, 16:4809-4821.
163. Qian L., Zhou L., Too H.-P., Chow G.-M. Gold decorated NaYF4:Yb, Er/NaYF4/silica (core/shell/shell) upconversion nanoparticles for photothermal destruction of BE(2)-C neuroblastoma cells. J. Nanoparticle Res. 2011, 13:499-510.
164. Lee P., Zhu Y., Yan J.J., Sun R.W.Y., Hao W., Liu X., Che C.M., Wong K.K.Y. The cytotoxic effects of lipidic formulated gold porphyrin nanoparticles for the treatment of neuroblastoma. Nanotechnol. Sci. Appl. 2010, 3:23-28.
165. Lee P., Zhang R., Li V., Liu X., Sun R.W., Che C.M., Wong K.K. Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation. Int. J. Nanomedicine 2012, 7:731-737.
166. Lum C.T., Yang Z.F., Li H.Y., Wai-Yin Sun R., Fan S.T., Poon R.T., Lin M.C., Che C.M., Kung H.F. Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma. Int. J. Cancer 2006, 118:1527-1538.
167. To Y.F., Sun R.W., Chen Y., Chan V.S., Yu W.Y., Tam P.K., Che C.M., Lin C.L. Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo. Int. J. Cancer 2009, 124:1971-1979.
168. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., Molema G., Lu P.Y., Scaria P.V., Woodle M.C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004, 32:e149.
169. The role of aromatic hydrocarbon receptor in the tumorigenesis of neuroblastoma and its relationship with MYCN expression in, (last accessed in June 2013). http://clinicaltrials.gov/ct2/show/NCT01075360.
170. Lee J.H., Jun Y.W., Yeon S.I., Shin J.S., Cheon J. Dual-mode nanoparticle probes for high-performance magnetic resonance and fluorescence imaging of neuroblastoma. Angew. Chem. Int. Ed. Engl. 2006, 45:8160-8162.
171. 2 nanoparticles with primary neural cells and their gene carrying performance. Biomaterials 2010, 31:6555-6566.
172. Lohmann D. Retinoblastoma. Adv. Exp. Med. Biol. 2010, 685:220-227.
173. Chintagumpala M., Chevez-Barrios P., Paysse E.A., Plon S.E., Hurwitz R. Retinoblastoma: review of current management. Oncologist 2007, 12:1237-1246.
174. Rodriguez-Galindo C., Wilson M.W., Chantada G., Fu L., Qaddoumi I., Antoneli C., Leal-Leal C., Sharma T., Barnoya M., Epelman S., Pizzarello L., Kane J.R., Barfield R., Merchant T.E., Robison L.L., Murphree A.L., Chevez-Barrios P., Dyer M.A., O'Brien J., Ribeiro R.C., Hungerford J., Helveston E.M., Haik B.G., Wilimas J. Retinoblastoma: one world, one vision. Pediatrics 2008, 122:e763-e770.
175. Abramson D.H., Schefler A.C. Update on retinoblastoma. Retina 2004, 24:828-848.
176. Carcaboso A.M., Chiappetta D.A., Opezzo J.A., Hocht C., Fandino A.C., Croxatto J.O., Rubio M.C., Sosnik A., Abramson D.H., Bramuglia G.F., Chantada G.L. Episcleral implants for topotecan delivery to the posterior segment of the eye. Invest. Ophthalmol. Vis. Sci. 2010, 51:2126-2134.
177. Schaiquevich P., Ceciliano A., Millan N., Taich P., Villasante F., Fandino A.C., Dominguez J., Chantada G.L. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr. Blood Cancer 2013, 60:766-770.
178. Parareda A., Català J., Carcaboso A.M., Sola T., Cruz O., Díaz J., Salvador H., de Torres C., Álvarez-Sampons A., Suñol M., Vinent J., Guimaraens L., Prat J., Mora J. Intra-arterial chemotherapy for retinoblastoma. Challenges of a prospective study. Acta Ophthalmol. 2014, 92:209-215.
179. Edelhauser H.F., Boatright J.H., Nickerson J.M. Drug delivery to posterior intraocular tissues: third Annual ARVO/Pfizer Ophthalmics Research Institute Conference. Invest. Ophthalmol. Vis. Sci. 2008, 49:4712-4720.
180. Wadhwa S., Paliwal R., Paliwal S.R., Vyas S.P. Nanocarriers in ocular drug delivery: an update review. Curr. Pharm. Des. 2009, 15:2724-2750.
181. Novack G.D. Eyes on new product development: ophthalmic drug delivery. J. Ocul. Pharmacol. Ther. 2013, 29:90-91.
182. Thrimawithana T.R., Young S., Bunt C.R., Green C., Alany R.G. Drug delivery to the posterior segment of the eye. Drug Discov. Today 2011, 16:270-277.
183. Kang S.J., Durairaj C., Kompella U.B., O'Brien J.M., Grossniklaus H.E. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch. Ophthalmol. 2009, 127:1043-1047.
184. Stephan H., Boeloeni R., Eggert A., Bornfeld N., Schueler A. Photodynamic therapy in retinoblastoma: effects of verteporfin on retinoblastoma cell lines. Invest. Ophthalmol. Vis. Sci. 2008, 49:3158-3163.
185. Makky A., Michel J.P., Maillard P., Rosilio V. Biomimetic liposomes and planar supported bilayers for the assessment of glycodendrimeric porphyrins interaction with an immobilized lectin. Biochim. Biophys. Acta 2011, 1808:656-666.
186. Makky A., Daghildjian K., Michel J.P., Maillard P., Rosilio V. Assessment of the relevance of supported planar bilayers for modeling specific interactions between glycodendrimeric porphyrins and retinoblastoma cells. Biochim. Biophys. Acta 2012, 1818:2831-2838.
187. Lupu M., Thomas C.D., Maillard P., Loock B., Chauvin B., Aerts I., Croisy A., Belloir E., Volk A., Mispelter J. 23Na MRI longitudinal follow-up of PDT in a xenograft model of human retinoblastoma. Photodiagnosis Photodyn. Ther. 2009, 6:214-220.
188. Makky A., Michel J.P., Ballut S., Kasselouri A., Maillard P., Rosilio V. Effect of cholesterol and sugar on the penetration of glycodendrimeric phenylporphyrins into biomimetic models of retinoblastoma cells membranes. Langmuir 2010, 26:11145-11156.
189. Gary-Bobo M., Mir Y., Rouxel C., Brevet D., Hocine O., Maynadier M., Gallud A., Da Silva A., Mongin O., Blanchard-Desce M., Richeter S., Loock B., Maillard P., Morere A., Garcia M., Raehm L., Durand J.O. Multifunctionalized mesoporous silica nanoparticles for the in vitro treatment of retinoblastoma: drug delivery, one and two-photon photodynamic therapy. Int. J. Pharm. 2012, 432:99-104.
190. Drago-Ferrante R., Santulli A., Di Fiore R., Giuliano M., Calvaruso G., Tesoriere G., Vento R. Low doses of paclitaxel potently induce apoptosis in human retinoblastoma Y79 cells by up-regulating E2F1. Int. J. Oncol. 2008, 33:677-687.
191. Das M., Sahoo S.K. Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS One 2012, 7:e32920.
192. Kim J.H., Kim K.W., Kim M.H., Yu Y.S. Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology 2009, 20:505101.
193. Melancon M.P., Stafford R.J., Li C. Challenges to effective cancer nanotheranostics. J. Control. Release 2012, 164:177-182.
194. Wang S., Mahesh S.P., Liu J., Geist C., Zderic V. Focused ultrasound facilitated thermo-chemotherapy for targeted retinoblastoma treatment: a modeling study. Exp. Eye Res. 2012, 100:17-25.
195. Smoll N.R. Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs). Cancer 2012, 118:1313-1322.
196. Northcott P.A., Hielscher T., Dubuc A., Mack S., Shih D., Remke M., Al-Halabi H., Albrecht S., Jabado N., Eberhart C.G., Grajkowska W., Weiss W.A., Clifford S.C., Bouffet E., Rutka J.T., Korshunov A., Pfister S., Taylor M.D. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol. 2011, 122:231-240.
197. Northcott P.A., Korshunov A., Witt H., Hielscher T., Eberhart C.G., Mack S., Bouffet E., Clifford S.C., Hawkins C.E., French P., Rutka J.T., Pfister S., Taylor M.D. Medulloblastoma comprises four distinct molecular variants. J. Clin. Oncol. 2011, 29:1408-1414.
198. Corcoran R.B., Scott M.P. Oxysterols stimulate sonic hedgehog signal transduction and proliferation of medulloblastoma cells. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8408-8413.
199. Gajjar A., Stewart C.F., Ellison D.W., Kaste S., Kun L.E., Packer R.J., Goldman S., Chintagumpala M., Wallace D., Takebe N., Boyett J.M., Gilbertson R.J., Curran T. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin. Cancer Res. 2013, 19:6305-6312.
200. Zhi F., Wang S., Wang R., Xia X., Yang Y. From small to big: microRNAs as new players in medulloblastomas. Tumour Biol. 2013, 34:9-15.
201. Chen K., Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat. Rev. Genet. 2007, 8:93-103.
202. Boiardi A., Pozzi A., Salmaggi A., Eoli M., Zucchetti M., Silvani A. Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors. Cancer Chemother. Pharmacol. 1999, 43:178-179.
203. Piccaluga P.P., Visani G., Martinelli G., Isidori A., Malagola M., Rondoni M., Baccarani M., Tura S. Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia. Leukemia 2002, 16:1880-1881.
204. Bomgaars L., Geyer J.R., Franklin J., Dahl G., Park J., Winick N.J., Klenke R., Berg S.L., Blaney S.M. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J. Clin. Oncol. 2004, 22:3916-3921.
205. Zucker D., Barenholz Y. Optimization of vincristine-topotecan combination-paving the way for improved chemotherapy regimens by nanoliposomes. J. Control. Release 2010, 146:326-333.
206. Lim K.J., Bisht S., Bar E.E., Maitra A., Eberhart C.G. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol. Ther. 2011, 11:464-473.
207. Meng W., Parker T.L., Kallinteri P., Walker D.A., Higgins S., Hutcheon G.A., Garnett M.C. Uptake and metabolism of novel biodegradable poly (glycerol-adipate) nanoparticles in DAOY monolayer. J. Control. Release 2006, 116:314-321.
208. Meng W., Kallinteri P., Walker D.A., Parker T.L., Garnett M.C. Evaluation of poly (glycerol-adipate) nanoparticle uptake in an in vitro 3-D brain tumor co-culture model. Exp. Biol. Med. (Maywood) 2007, 232:1100-1108.
209. Riehemann K., Schneider S.W., Luger T.A., Godin B., Ferrari M., Fuchs H. Nanomedicine-challenge and perspectives. Angew. Chem. Int. Ed. Engl. 2009, 48:872-897.
210. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. 2011, 8:2101-2141.
211. Svenson S. Theranostics: are we there yet?. Mol. Pharm. 2013, 10:848-856.
212. Sun C., Fang C., Stephen Z., Veiseh O., Hansen S., Lee D., Ellenbogen R.G., Olson J., Zhang M. Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. Nanomedicine (London) 2008, 3:495-505.
213. Veiseh O., Kievit F.M., Gunn J.W., Ratner B.D., Zhang M. A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials 2009, 30:649-657.
214. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
215. Huse J.T., Phillips H.S., Brennan C.W. Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 2011, 59:1190-1199.
216. Lima F.R., Kahn S.A., Soletti R.C., Biasoli D., Alves T., da Fonseca A.C., Garcia C., Romao L., Brito J., Holanda-Afonso R., Faria J., Borges H., Moura-Neto V. Glioblastoma: therapeutic challenges, what lies ahead. Biochim. Biophys. Acta 2012, 1826:338-349.
217. Rodriguez F.J., Lim K.S., Bowers D., Eberhart C.G. Pathological and molecular advances in pediatric low-grade astrocytoma. Annu. Rev. Pathol. 2013, 8:361-379.
218. Lubrich B., van Calker D., Peschka-Suss R. Inhibition of inositol uptake in astrocytes by antisense oligonucleotides delivered by pH-sensitive liposomes. Eur. J. Biochem. 2000, 267:2432-2438.
219. Dickinson P.J., LeCouteur R.A., Higgins R.J., Bringas J.R., Larson R.F., Yamashita Y., Krauze M.T., Forsayeth J., Noble C.O., Drummond D.C., Kirpotin D.B., Park J.W., Berger M.S., Bankiewicz K.S. Canine spontaneous glioma: a translational model system for convection-enhanced delivery. Neuro. Oncol. 2010, 12:928-940.
220. Bethune C.R., Geyer R.J., Spence A.M., Ho R.J. Lipid association improves the therapeutic index of lomustine [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea] to suppress 36B-10 tumor growth in rats. Cancer Res. 2001, 61:3669-3674.
221. Fabel K., Dietrich J., Hau P., Wismeth C., Winner B., Przywara S., Steinbrecher A., Ullrich W., Bogdahn U. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 2001, 92:1936-1942.
222. Madhankumar A.B., Slagle-Webb B., Wang X., Yang Q.X., Antonetti D.A., Miller P.A., Sheehan J.M., Connor J.R. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol. Cancer Ther. 2009, 8:648-654.
223. Gupta B., Torchilin V.P. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol. Immunother. 2007, 56:1215-1223.
224. Arndt C.A., Crist W.M. Common musculoskeletal tumors of childhood and adolescence. N. Engl. J. Med. 1999, 341:342-352.
225. Iwamoto Y. Diagnosis and treatment of Ewing's sarcoma. Jpn. J. Clin. Oncol. 2007, 37:79-89.
226. Hu-Lieskovan S., Heidel J.D., Bartlett D.W., Davis M.E., Triche T.J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 2005, 65:8984-8992.
227. Toub N., Bertrand J.R., Tamaddon A., Elhamess H., Hillaireau H., Maksimenko A., Maccario J., Malvy C., Fattal E., Couvreur P. Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm. Res. 2006, 23:892-900.
228. Alhaddad A., Adam M.P., Botsoa J., Dantelle G., Perruchas S., Gacoin T., Mansuy C., Lavielle S., Malvy C., Treussart F., Bertrand J.R. Nanodiamond as a vector for siRNA delivery to Ewing sarcoma cells. Small 2011, 7:3087-3095.
229. Wunder J.S., Nielsen T.O., Maki R.G., O'Sullivan B., Alman B.A. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol. 2007, 8:513-524.
230. Prieur A., Tirode F., Cohen P., Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell. Biol. 2004, 24:7275-7283.
231. Malempati S., Hawkins D.S. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr. Blood Cancer 2012, 59:5-10.
232. Amankwah E.K., Conley A.P., Reed D.R. Epidemiology and therapies for metastatic sarcoma. Clin. Epidemiol. 2013, 5:147-162.
233. van Bree C., Krooshoop J.J., Rietbroek R.C., Kipp J.B., Bakker P.J. Hyperthermia enhances tumor uptake and antitumor efficacy of thermostable liposomal daunorubicin in a rat solid tumor. Cancer Res. 1996, 56:563-568.
234. Morita K., Zywietz F., Kakinuma K., Tanaka R., Katoh M. Efficacy of doxorubicin thermosensitive liposomes (40 degrees C) and local hyperthermia on rat rhabdomyosarcoma. Oncol. Rep. 2008, 20:365-372.
235. Gao Z.G., Fain H.D., Rapoport N. Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J. Control. Release 2005, 102:203-222.
236. Munshi N., Rapoport N., Pitt W.G. Ultrasonic activated drug delivery from Pluronic P-105 micelles. Cancer Lett. 1997, 118:13-19.
237. Rapoport N.Y., Herron J.N., Pitt W.G., Pitina L. Micellar delivery of doxorubicin and its paramagnetic analog, ruboxyl, to HL-60 cells: effect of micelle structure and ultrasound on the intracellular drug uptake. J. Control. Release 1999, 58:153-162.
238. Husseini G.A., El-Fayoumi R.I., O'Neill K.L., Rapoport N.Y., Pitt W.G. DNA damage induced by micellar-delivered doxorubicin and ultrasound: comet assay study. Cancer Lett. 2000, 154:211-216.
239. Husseini G.A., Christensen D.A., Rapoport N.Y., Pitt W.G. Ultrasonic release of doxorubicin from Pluronic P105 micelles stabilized with an interpenetrating network of N, N-diethylacrylamide. J. Control. Release 2002, 83:303-305.
240. Rapoport N. Combined cancer therapy by micellar-encapsulated drug and ultrasound. Int. J. Pharm. 2004, 277:155-162.
241. Stevenson-Abouelnasr D., Husseini G.A., Pitt W.G. Further investigation of the mechanism of doxorubicin release from P105 micelles using kinetic models. Colloids Surf. B: Biointerfaces 2007, 55:59-66.
242. Zeisberger S.M., Odermatt B., Marty C., Zehnder-Fjallman A.H., Ballmer-Hofer K., Schwendener R.A. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 2006, 95:272-281.
243. Tacar O., Sriamornsak P., Dass C.R. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 2013, 65:157-170.
244. Killion J.J., Fidler I.J. Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators. Pharmacol. Ther. 1998, 78:141-154.
245. Knight V., Kleinerman E.S., Waldrep J.C., Giovanella B.C., Gilbert B.E., Koshkina N.V. 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann. N. Y. Acad. Sci. 2000, 922:151-163.
246. Koshkina N.V., Kleinerman E.S., Waidrep C., Jia S.F., Worth L.L., Gilbert B.E., Knight V. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin. Cancer Res. 2000, 6:2876-2880.
247. Vail D.M., Kurzman I.D., Glawe P.C., O'Brien M.G., Chun R., Garrett L.D., Obradovich J.E., Fred R.M., Khanna C., Colbern G.T., Working P.K. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother. Pharmacol. 2002, 50:131-136.
248. Meyers P.A., Schwartz C.L., Krailo M., Kleinerman E.S., Betcher D., Bernstein M.L., Conrad E., Ferguson W., Gebhardt M., Goorin A.M., Harris M.B., Healey J., Huvos A., Link M., Montebello J., Nadel H., Nieder M., Sato J., Siegal G., Weiner M., Wells R., Wold L., Womer R., Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol. 2005, 23:2004-2011.
249. Kager L., Potschger U., Bielack S. Review of mifamurtide in the treatment of patients with osteosarcoma. Ther. Clin. Risk Manag. 2010, 6:279-286.
250. Dhule S.S., Penfornis P., Frazier T., Walker R., Feldman J., Tan G., He J., Alb A., John V., Pochampally R. Curcumin-loaded gamma-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine 2012, 8:440-451.
251. Loukas Y.L., Vraka V., Gregoriadis G. Drugs, in cyclodextrins, in liposomes: a novel approach to the chemical stability of drugs sensitive to hydrolysis. Int. J. Pharm. 1998, 162:137-142.
252. Tran P.A., Sarin L., Hurt R.H., Webster T.J. Titanium surfaces with adherent selenium nanoclusters as a novel anticancer orthopedic material. J. Biomed. Mater. Res. A 2010, 93:1417-1428.
253. Tran P.A., Sarin L., Hurt R.H., Webster T.J. Differential effects of nanoselenium doping on healthy and cancerous osteoblasts in coculture on titanium. Int. J. Nanomedicine 2010, 5:351-358.
254. Ta H.T., Dass C.R., Larson I., Choong P.F., Dunstan D.E. A chitosan-dipotassium orthophosphate hydrogel for the delivery of doxorubicin in the treatment of osteosarcoma. Biomaterials 2009, 30:3605-3613.
255. Tan M.L., Friedhuber A.M., Dunstan D.E., Choong P.F., Dass C.R. The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model. Biomaterials 2010, 31:541-551.
256. Kubo T., Sugita T., Shimose S., Nitta Y., Ikuta Y., Murakami T. Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. Int. J. Oncol. 2001, 18:121-125.
257. Nobuto H., Sugita T., Kubo T., Shimose S., Yasunaga Y., Murakami T., Ochi M. Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet. Int. J. Cancer 2004, 109:627-635.
258. Shimose S., Sugita T., Nitta Y., Kubo T., Ikuta Y., Murakami T. Effect of thermosensitive liposomal doxorubicin with hyperthermia on primary tumor and lung metastases in hamster osteosarcoma. Int. J. Oncol. 2001, 19:585-589.
259. Matsuoka F., Shinkai M., Honda H., Kubo T., Sugita T., Kobayashi T. Hyperthermia using magnetite cationic liposomes for hamster osteosarcoma. Biomagn. Res. Technol. 2004, 2:3.
260. Ueno Y., Sonoda S., Suzuki R., Yokouchi M., Kawasoe Y., Tachibana K., Maruyama K., Sakamoto T., Komiya S. Combination of ultrasound and bubble liposome enhance the effect of doxorubicin and inhibit murine osteosarcoma growth. Cancer Biol. Ther. 2011, 12:270-277.
261. Davies Cde L., Lundstrom L.M., Frengen J., Eikenes L., Bruland S.O., Kaalhus O., Hjelstuen M.H., Brekken C. Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. Cancer Res. 2004, 64:547-553.
262. Eikenes L., Tari M., Tufto I., Bruland O.S., de Lange Davies C. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br. J. Cancer 2005, 93:81-88.
263. Sun K., Wang J., Zhang J., Hua M., Liu C., Chen T. Dextran-g-PEI nanoparticles as a carrier for co-delivery of adriamycin and plasmid into osteosarcoma cells. Int. J. Biol. Macromol. 2011, 49:173-180.
264. Dass C.R., Friedhuber A.M., Khachigian L.M., Dunstan D.E., Choong P.F. Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model. Cancer Biol. Ther. 2008, 7:1033-1036.
265. Dass C.R., Contreras K.G., Dunstan D.E., Choong P.F. Chitosan microparticles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic metastatic model of osteosarcoma. Biomaterials 2007, 28:3026-3033.
266. Dutour A., Monteil J., Paraf F., Charissoux J.L., Kaletta C., Sauer B., Naujoks K., Rigaud M. Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol. Ther. 2005, 11:311-319.
267. Anada T., Takeda Y., Honda Y., Sakurai K., Suzuki O. Synthesis of calcium phosphate-binding liposome for drug delivery. Bioorg. Med. Chem. Lett. 2009, 19:4148-4150.
268. Wu D., Wan M. Methylene diphosphonate-conjugated adriamycin liposomes: preparation, characteristics, and targeted therapy for osteosarcomas in vitro and in vivo. Biomed. Microdevices 2012, 14:497-510.
269. Gorlick R., Huvos A.G., Heller G., Aledo A., Beardsley G.P., Healey J.H., Meyers P.A. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol. 1999, 17:2781-2788.
270. Baselga J., Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 2005, 23:2445-2459.
271. Shan L.Q., Qiu X.C., Xu Y.M., Ji Z.G., Yang T.T., Chen X., Ma B.A., Zhou Y., Fan Q.Y., Yang A.G. scFv-mediated delivery of truncated BID suppresses HER2-positive osteosarcoma growth and metastasis. Cancer Biol. Ther. 2008, 7:1717-1722.
272. Calzolari A., Oliviero I., Deaglio S., Mariani G., Biffoni M., Sposi N.M., Malavasi F., Peschle C., Testa U. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol. Dis. 2007, 39:82-91.
273. Nakase M., Inui M., Okumura K., Kamei T., Nakamura S., Tagawa T. p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol. Cancer Ther. 2005, 4:625-631.
274. Segal E., Pan H., Benayoun L., Kopeckova P., Shaked Y., Kopecek J., Satchi-Fainaro R. Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. Biomaterials 2011, 32:4450-4463.
275. Nanotechnology in medical applications: the global market (HLC069B). BCC Research in, (last accessed in March 2013). http://www.bccresearch.com/report/nanotechnology-medical-applications-global-market-hlc069b.html.
276. McCabe E.R. Nanopediatrics: enabling personalized medicine for children. Pediatr. Res. 2010, 67:453-457.
277. NanoPediatrics in, (last accessed in May 2013). http://www.nanopediatrics.ucla.edu/.
278. Center for Pediatric Medicine in, (last accessed in May 2013). http://www.pedsresearch.org/centers/detail/pediatric-nanotechnology.
279. Australian Centre for NanoMedicine (ACN) in, (last accessed in May 2013). http://www.acn.unsw.edu.au/.
280. Stoyanova-Beninska V.V., Wohlfarth T., Isaac M., Kalverdijk L.J., van den Berg H., Gispen-de Wied C. The EU paediatric regulation: effects on paediatric psychopharmacology in Europe. Eur. Neuropsychopharmacol. 2011, 21:565-570.
281. Zwaan C.M., Kearns P., Caron H., Verschuur A., Riccardi R., Boos J., Doz F., Geoerger B., Morland B., Vassal G. The role of the 'innovative therapies for children with cancer' (ITCC) European consortium. Cancer Treat. Rev. 2010, 36:328-334.
282. Boots I., Sukhai R.N., Klein R.H., Holl R.A., Wit J.M., Cohen A.F., Burggraaf J. Stimulation programs for pediatric drug research-do children really benefit?. Eur. J. Pediatr. 2007, 166:849-855.
283. Jacqz-Aigrain E. Drug policy in Europe Research and funding in neonates: current challenges, future perspectives, new opportunities. Early Hum. Dev. 2011, 87(Suppl. 1):S27-S30.
284. Eunice Kennedy Shriver National Institute of Child Health and Human Development in, (last accessed June 2013). http://www.nichd.nih.gov.
285. Giacoia G.P., Taylor-Zapata P., Mattison D. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups. Clin. Ther. 2008, 30:2097-2101.
286. European Paediatric Formulation Initiative, in, (last accessed June 2013). http://www.eupfi.org.
287. Global Research in Pediatrics - Network of Excellence in, (last accessed June 2013). http://www.grip-network.org.
288. Cram A., Breitkreutz J., Desset-Brethes S., Nunn T., Tuleu C. Challenges of developing palatable oral paediatric formulations. Int. J. Pharm. 2009, 365:1-3.